Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beryl DrugsBOM:524606 +7.85%70 Gross Margin % is 39.10% as of Mar. 2026, which is 26% above its 10-year median of 30.97. GuruFocus rates BOM:524606 with a GF Score™ of 70/100 and a GF Value™ of ₹20.66 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 941 Drug Manufacturers companies, Beryl Drugs ranks worse than 50.48% on this metric.
The historical rank and industry rank for Beryl Drugs's Gross Margin % or its related term are showing as below:
BOM:524606'
s Gross Margin % Range Over the Past 10 Years
Min: 24.73 Med: 30.97 Max: 49
Current: 48.11
During the past 13 years, the highestGross Margin % of Beryl Drugs was 49.00%. The lowest was 24.73%. And the median was 30.97%.
BOM:524606's Gross Margin % is ranked worse than 50.48% of 941
companies
in the Drug Manufacturers industry
Industry Median: 48.42
vs BOM:524606: 48.11
Beryl Drugs had a gross margin of 39.10% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Beryl Drugs was 11.60% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Beryl Drugs had a gross margin of 39.10% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Beryl Drugs Gross Margin % Related Terms
Beryl Drugs Gross Margin % Historical Data
* Premium members only.
The historical data trend for Beryl Drugs's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beryl Drugs Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Beryl Drugs's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Beryl Drugs (BOM:524606) has a Gross Margin % of 39.10% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Beryl Drugs and its competitors. This is 26% above median its historical median of 30.97. Over the past decade, Beryl Drugs' Gross Margin % has ranged from 24.73 to 49.00. According to the industry distribution chart, Beryl Drugs ranks #475 out of 941 companies in the Drug Manufacturers industry, placing it in the top 50.5%.
Is Beryl Drugs' Gross Margin % too high?
Beryl Drugs' current Gross Margin % of 39.10% is 26% above median its 10-year median of 30.97. Over the past 10 years, this metric has ranged from a low of 24.73 to a high of 49.00. The Drug Manufacturers industry median Gross Margin % is 48.42. Beryl Drugs' value of 39.10% is 19.2% below this industry median. Based on the distribution chart, Beryl Drugs ranks #475 out of 941 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Beryl Drugs has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beryl Drugs' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beryl Drugs ranks #475 out of 941 companies for Gross Margin %. This places Beryl Drugs in the lower half of its industry. The industry median Gross Margin % is 48.42. Beryl Drugs' value of 39.10% is 19.2% below this benchmark. Historically, Beryl Drugs' own Gross Margin % has ranged from 24.73 to 49.00 over the past decade. While the company's 10-year median is 30.97 vs. the industry median of 48.42, Beryl Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.42, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beryl Drugs's current Gross Margin % of 39.10% is 19.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Beryl Drugs and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beryl Drugs's current Gross Margin % is 39.10%, which is 26% above median its own 10-year median of 30.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beryl Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beryl Drugs (BOM:524606) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹20.66, compared to a current price of ₹24.04 — trading 16.4% above its estimated fair value. The current Gross Margin % is 39.10%, which is 26% above median its 10-year median of 30.97 and 19.2% below the Drug Manufacturers industry median of 48.42. Beryl Drugs' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Beryl Drugs (BOM:524606), the current Gross Margin % is 39.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beryl Drugs (BOM:524606) Overvalued in 2026?
Based on GuruFocus' analysis, Beryl Drugs stock appears to be overvalued.
The current stock price of ₹24.04 is trading 16.4% above its estimated GF Value™ of ₹20.66.
GuruFocus considers Beryl Drugs to be Modestly Overvalued.
Key valuation signals for BOM:524606:
Gross Margin %: 39.10% (26% above median its 10-year median of 30.97)
GF Value™: ₹20.66 vs. price of ₹24.04 (16.4% above fair value)
Industry Position: 19.2% below the Drug Manufacturers median (#475 of 941)
No single metric tells the full story. See the BOM:524606 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.
70GF Score
Get the complete analysis for BOM:524606
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524606 has been successfully added to your 
